Is emgality effective for treating cluster headaches?

Is Emgality effective for cluster headaches?

Emgality (galcanezumab) is the only CGRP monoclonal antibody approved by the FDA for the preventive treatment of episodic cluster headaches. It works by blocking the calcitonin gene-related peptide (CGRP) pathway, which is involved in the pain signaling that drives cluster attacks.

How well does it reduce attacks?

In the pivotal phase 3 trial, patients using Emgality experienced an average reduction of 8.7 cluster headache attacks per week compared with 5.2 attacks for placebo during weeks 1–3 of treatment. The difference reached statistical significance. Many participants saw at least a 50% reduction in weekly attacks.

How fast does it work?

Emgality can begin to lower attack frequency within the first week. This rapid onset distinguishes it from many oral preventives that may take several weeks to show benefit.

Who should consider it?

It is indicated for adults with episodic cluster headache. Patients with chronic cluster headache were studied in a separate trial that did not meet its primary endpoint, so the drug is not approved for that form.

What are the main side effects?

The most common side effects reported are injection-site reactions. Because Emgality is given as a monthly subcutaneous injection, some patients also experience mild pain or redness at the injection site.

How does it compare with other options?

Traditional preventives such as verapamil or lithium require daily oral dosing and can have more systemic side effects. Emgality offers a once-monthly injection with a targeted mechanism, but it is considerably more expensive and may not be covered by every insurance plan without prior authorization.

When does patent protection end?

The composition-of-matter patent for galcanezumab is listed to expire in 2031 on DrugPatentWatch.com, although additional patents on formulation or methods of use could extend market exclusivity.